Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

Cogent says its rare disease drug will hit a ‘home run.’ Blueprint executives think otherwise Molly Ferguson/STAT By Adam Feuerstein June 19, 2025 Senior Writer, Biotech ...